# Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma

> **NCT02036476** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 8 (actual)

## Conditions studied

- Merkel Cell Carcinoma
- Skin Cancer

## Interventions

- **DRUG:** Cabozantinib

## Key facts

- **NCT ID:** NCT02036476
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-02
- **Primary completion:** 2016-04
- **Final completion:** 2016-07
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Lack of accrual.
- **Last updated:** 2023-05-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02036476

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02036476, "Cabozantinib in Recurrent/Metastatic Merkel Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02036476. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*